Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.54 - $3.97
Previous CloseN/A
Volume977.37K
Average Volume (3M)3.29M
Market Cap
$738.37M
Enterprise ValueN/A
Total Cash (Recent Filing)$502.69M
Total Debt (Recent Filing)$8.91M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Aug 06, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding339,262,970
10 Day Avg. Volume3,312,738
30 Day Avg. Volume3,289,988
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.47
Price to Sales (P/S)0.00
P/FCF Ratio-5.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.20Price Target Upside264.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio Holds Successful Annual Meeting 2025
PremiumCompany Announcements
Nuvation Bio Reports Q1 2025 Results and Business Updates
Bulls Say, Bears Say
Bulls Say
FinancingStock is now set up for success with $250M royalty financing removing further overhangs.
Market OpportunityNew NCCN guidelines increase taletrectinib market opportunity by removing IO/chemo for 1L.
Regulatory ApprovalNuvation has been granted a priority review by the FDA, and management anticipates a line-agnostic full approval.
Bears Say
Market SizeThere is a risk that the ROS1+ NSCLC market is small, and the sales ramp for taletrectinib is likely to be slow.
Regulatory DelaysTwo PDUFA dates have now been missed since the recent cuts at the FDA, which may concern investors.
Ownership Overview
27.24% Insiders
15.50% Mutual Funds
22.72% Other Institutional Investors
25.89% Public Companies and Individual Investors
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $3.97 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $738.37M.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Aug 06, 2025 which is in 74 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on May 07, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.153 by -$0.007.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.16.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 339,262,970 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.153. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (264.44% Upside)
$8.20 (264.44% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $818.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.1%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-119.66%
Trailing 12-Months
Asset Growth
-19.68%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong confidence in the potential approval and market launch of taletrectinib. The company highlighted its robust financial position and pipeline development, although there were concerns about increased expenses and gaps in patient testing and diagnosis.Read More>NUVB Stock 12 Month Forecast
Average Price Target
$8.20
▲( 264.44% Upside)
Technical Analysis
Arbutus Biopharma
―
Xencor
―
Rocket Pharmaceuticals
―
Praxis Precision Medicines
―
Bicara Therapeutics Inc.
―